Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Prophylaxis for Glucocorticoid-Induced Hyperglycemia
NCT06748105Phase 2Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in glucocorticoid-induced hyperglycemia (GIDM) (2 arms). Primary endpoints: Incidence of glucocorticoid-induced hyperglycemia and Incidence of hyperglycemia crisis. Started Dec 2024; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
glucocorticoid-induced hyperglycemia (GIDM)
Beyond the preview
Go deeper on NCT06748105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748105.